Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

IMPORTANCE: Despite approximately 40% of patients having Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark clinical trials that led to the use of pembrolizumab as standard of care in advanced non–small cell lung cancer (NSCLC) exc...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Netw Open
Auteurs principaux: Sehgal, Kartik, Gill, Ritu R., Widick, Page, Bindal, Poorva, McDonald, Danielle C., Shea, Meghan, Rangachari, Deepa, Costa, Daniel B.
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2021
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7879233/
https://ncbi.nlm.nih.gov/pubmed/33570575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.37120
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires